Imaging management of cystic pancreatic lesions

THE CLINICAL BURDEN

Incidental pancreatic cysts are no longer a radiological curiosity: Up to 15% of abdominal magnetic resonance imaging (MRI) studies reveal an unsuspected lesion, and prevalence rises to >25% in septuagenarians.^[1] The challenge is obvious: screen out the rare high-grade dysplasia or cancer while sparing the majority of patients from life-long, costly surveillance. Evidence-based imaging pathways have therefore moved Centre-stage in everyday practice.

As known, MRI is the most readily accessible modality, offering the best cost-to-diagnostic performance ratio currently available. However, before designing any protocol, the radiologist should keep two simple questions in mind:

• Which MR-sequences give the best cost-diagnostic accuracy ratio?

• For how long should surveillance be tailored?

The answers are evolving, but current guidelines converge on several pragmatic principles.

DETECTION

Abdominal contrast-enhanced MRI/magnetic resonance cholangiopancreatography (MRCP) is the preferred first-line investigation for a newly detected pancreatic cyst. Indeed, it demonstrates ductal communication, septa, and mural nodules.^[2] Specifically, the strongest independent predictor of malignancy is the presence of a mural nodule.^[3] Moreover, diffusion-weighted imaging (DWI) emerged as a useful adjunct with restricted diffusion within a mural nodule often correlates with high-grade dysplasia.^[4]

When MRI is contraindicated, a dedicated pancreatic computed tomography is an acceptable fallback. Ultrasound and contrast-enhanced endoscopic ultrasound (EUS) remain complementary rather than primary triage tools.^[5]

CHARACTERIZING THE LESION

For IPMN, key baseline descriptors are distilled into a three-tier classification: branch-duct, main-duct, or mixed.^[6] A main pancreatic duct (MPD) diameter ≥5 mm, even in the absence of upstream obstruction, classifies the lesion as “main-duct or mixed” a category associated with a higher risk of malignancy.

Once the IPMN is confirmed, three imaging hallmarks dominate management decisions:

1. Cyst diameter: thresholds of 30–40 mm trigger closer follow-up or upfront surgery^[2,7]

2. MPD dilatation: 5–9 mm is a worrisome feature, ≥10 mm is a high-risk stigma^[7]

3. Enhancing mural nodule or solid component: Any nodule ≥5 mm that enhances on dynamic post-contrast MRI or contrast-enhanced (CE)-EUS is a direct red-flag for resection.^[5]

Mucinous cystadenoma (MCN) are typically solitary and detected in younger women. They should be resected when ≥40 mm or symptomatic, whereas smaller lesions may be monitored biennially in surgery-unfit patients.^[1]

Serous cystadenomas are overwhelmingly benign, with <1% documented malignant transformation.^[1,6] When the diagnosis is secure, mainly based on microcystic “honeycomb” architecture, central scar, and no ductal communication, no routine follow-up is necessary.

SURVEILLANCE PROTOCOLS

The consensus is coalescing around short, MRI-centered protocols, based on T2 2D Half-Fourier acquisition single-shot turbo spin echo (HASTE), T2 2D FS, echo planar imaging (EPI)-DWI, T1 DIXON fat suppression (DIXON FS), 2D MRCP.^[5] These sequences capture size, MPD diameter and nodules in <10 min and without gadolinium. When cysts are <30 mm, show no nodule, and the MPD is <5 mm, an 18-month interval is adequate; if any worrisome feature develops, switch to an annual (or 6-monthly) full protocol with contrast.^[7]

The updated Kyoto guidelines allow the clinician to discontinue imaging after 5 years of stability for a branch-duct IPMN <20 mm, for patient over 75 years or otherwise unfit for surgery.^[7] Stopping rules remain controversial. Patients with a positive family history of pancreatic cancer, however, retain a lifelong, albeit low-intensity, schedule.

TOWARDS A RIGOROUS APPROACH

Radiologists must look beyond cyst morphology. Concomitant pancreatic ductal adenocarcinoma develops in 6% of IPNMs, often in a separate segment.

Equally important is structured reporting, focusing the reader to cyst size, MPD diameter and especially presence/size of nodules.

Finally, in particular for high-volume pancreatic disease centers, radiologist should consider the use of short protocol, avoiding any reduction of diagnostic reliability thus making possible light continuous follow up. In young patients after many decades you the neoplasms have more time to develop from pathological point of view.

CONCLUSION

Imaging now drives the entire clinical algorithm for cystic pancreatic lesions: it decides who to operate, when to watch, how to continue follow up easily but in accurate way and when to stop. Fast, high-resolution MRI, improved by selective EUS-fine needle aspiration (FNA), anchors the process. As guidelines mature and short protocols proliferate, radiologists must lead the charge toward uniform, patient-centred, and resource-sensible care.